This trend emphasizes the development of individualized treatment strategies that align therapeutic interventions with the specific symptoms and comorbidities of patients. When clinicians are not well-versed in the syndrome's symptoms or treatment strategies, they may overlook opportunities for appropriate care, often resulting in conservative management options. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The growing diagnosis and awareness of Klinefelter syndrome are significantly driving the therapeutics market, increasing the demand for endocrine, fertility, and neurodevelopmental treatments. From the onset of puberty, the existing testosterone deficiency can be compensated by appropriate hormone-replacement therapy. The lifespan of individuals with Klinefelter syndrome appears to be reduced by around 2.1 years compared to the general male population.
Endocrine Society is a global community of physicians and scientists dedicated to accelerating scientific breakthroughs and improving patient health and well being. For 100 years, the Endocrine Society has been at the forefront of hormone science and public health. Our specialists are nationally ranked and globally recognized for delivering the best possible care in pediatrics. Learn how we're addressing community health needs Pediatric cardiologist Kathleen Simpson, MD, was elected to leadership of the Pediatric Heart Transplant Society, a national honor recognizing her impact on transplant care. Researchers analyzed new Dravet syndrome treatment for efficacy and safety. Instead, clinicians should closely monitor and assess these patients for early intervention needs from birth until age 5.
Since treatment will likely be lifelong, we at our clinic encourage patients to use both transdermal and injectable formulations for a period of at least 6 months to find the one treatment best suited for them. The men in the cohort of untreated KS are either individuals that have not yet reached puberty or individuals that are on overage born 12 years earlier than the testosterone-treated cohort. This suggests that the delay in treatment is more likely due to failure of providers outside these specialized centers to recommend appropriate treatment and could indicate a lapse of care of men with KS, even in a health care system as accessible as the Danish system.
Without treatment, the shortage of testosterone can lead to delayed or incomplete puberty, breast enlargement (gynecomastia), decreased muscle mass, decreased bone density, a reduced amount of facial and body hair, and fatigue. Following testosterone replacement therapy, untreated-Klinefelter syndrome showed significant reductions in coagulation factor XII and C1 esterase inhibitor. Untreated Klinefelter syndrome initiated testosterone replacement therapy at baseline. This clinical ambiguity diminishes the prioritization of Klinefelter syndrome within healthcare systems and hampers demand for innovative therapies, ultimately discouraging investment and hindering the progress of targeted treatment development and implementation.
In the following, we present a condensation of the available literature reporting health outcomes of testosterone treatment in KS in adults, and, when available in boys and adolescents. As such, major guidelines for testosterone treatment all agree that hypogonadism in men should be treated (Salter & Mulhall, 2019). "He will need testosterone replacement therapy when he is older since his body will produce low testosterone. Will he be denied his gender-affirming care?" "Gender-affirming care is just not for transgender youth," she explained, asserting that it would impact her son, who will require testosterone replacement therapy later in life due to low natural testosterone production. The global market for Klinefelter Syndrome therapeutics is significantly driven by advancements in hormonal therapy, which have broadened treatment options and bolstered confidence among healthcare professionals.
Also, there are indications of a positive effect of early testosterone supplementation on improving the behavioral phenotype in boys with KS (Samango-Sprouse et al., 2015), although these studies are purely observational and without proper randomization and inclusion of a placebo-treated control group of males with KS. In the study by Close et al. no association between quality of life and total testosterone level in blood were seen (Chang et al., 2015). To further understand the underlying cause of the decrement in quality of life seen in boys and men with KS, some of the studies investigated several variables that might be important predictors of quality of life. Overall, these studies unequivocally reported decreased quality of life or aspects of quality of life in boys, adolescents and adults with KS. As exemplified by a recent case presentation of prostatic cancer in a testosterone-treated man with KS (Nishikawa, Jia, Dharamshi, Charron, & Lock, 2019), there has been concern that treatment could increase the risk of prostatic cancer in men with KS. Future intervention studies should carefully assess the effect of testosterone on testicular function and the hypothalamic–pituitary axis in both prepubertal and postpubertal boys. Spermatogenesis requires high intratesticular testosterone stimulated by LH, therefore there is concern that testosterone treatment may reduce the success of fertility treatments in individuals with KS.

Gender: Female

Social links